Intravenous administration of allogeneic canine gonadal tissue-derived mesenchymal stem cells was associated with significant six-month reductions in circulating cardiac biomarkers and specific cardiac imaging measurements among client-owned dogs diagnosed with early-stage myxomatous mitral valve disease, according to results from the prospective comparative SPRING pilot study.
Myxomatous mitral valve disease is primarily degenerative in nature, and routine pharmacological treatment is not currently recommended at stage B1. In veterinary regenerative medicine, mesenchymal stem cells represent multipotent stromal cells recognized for their capacity to promote tissue repair while exerting immunomodulatory and anti-inflammatory effects. The exploratory trial sought to evaluate whether systemic delivery of allogeneic gonadal tissue-derived cells could alter disease markers during this early phase before standard pharmaceuticals are indicated.
The analyzed study cohort comprised ten client-owned dogs diagnosed with stage B1 myxomatous mitral valve disease. Allocation into the trial cohorts was determined according to owners’ treatment choices, resulting in five dogs assigned to receive mesenchymal stem cell therapy and five dogs followed as non-treated controls.
Treated dogs received systemic intravenous infusions of allogeneic canine gonadal tissue-derived mesenchymal stem cells at a dosage of 1 × 10^6 cells per kilogram of body weight. These intravenous administrations were delivered at regular monthly intervals for four total infusions, and all ten participating dogs were followed over a six-month observation timeline.
The exploratory investigation primarily assessed changes in circulating serum transforming growth factor-β1 following stem cell administration, alongside N-terminal pro-B-type natriuretic peptide and echocardiographic measurements as secondary clinical outcomes. Compared with controls, treated dogs demonstrated significantly greater decreases from baseline to six months in serum transforming growth factor-β1 (p = 0.0317) as well as N-terminal pro-B-type natriuretic peptide (p = 0.0079). The mean-change difference for N-terminal pro-B-type natriuretic peptide was −530.38 pmol/L, with a Welch 95 percent confidence interval ranging from −846.19 to −214.57 pmol/L, although absolute concentrations did not differ significantly between cohorts at either visit.
Echocardiographic and anatomical assessments revealed corresponding differences between the study groups over the six-month study period. Treated dogs exhibited significantly greater decreases in body weight-normalized anterior mitral leaflet area compared with controls (p = 0.0079), a finding that remained statistically significant after both Holm- and Bonferroni-adjustment (p = 0.0238). In addition, changes in body weight-normalized left ventricular end-diastolic internal diameter (p = 0.0397) and vertebral left atrial size (p = 0.0079) decreased to a significantly greater extent in the stem cell group.
While these prospective comparative observations demonstrate measurable associations between gonadal tissue-derived stem cell therapy and favorable biomarker shifts in early degenerative valve disease, the researchers noted essential constraints in study design. The pilot investigation evaluated a small cohort of ten client-owned dogs without blinded randomization. Consequently, the investigative team concluded that larger randomized studies will be needed to verify whether these preliminary physiological changes can translate into sustained clinical benefit for canine cardiac patients.
Subject of Research: Mesenchymal stem cell therapy for canine myxomatous mitral valve disease
Article Title: Canine gonadal tissues-derived mesenchymal stem cell therapy for early myxomatous mitral valve disease in dogs: the SPRING study, a prospective comparative pilot study
Article References: Jeung, S., Lim, G.-H., Song, S.-H., Jung, Y., Lim, S., & Kim, S.-S. (2026). Canine gonadal tissues-derived mesenchymal stem cell therapy for early myxomatous mitral valve disease in dogs: the SPRING study, a prospective comparative pilot study. BMC Veterinary Research. https://doi.org/10.1186/s12917-026-06087-2
Image Credits: AI Generated
DOI: 10.1186/s12917-026-06087-2
Keywords: mesenchymal stem cells, myxomatous mitral valve disease, canine cardiology, gonadal tissue-derived MSCs, stage B1 MMVD, TGF-β1, NT-proBNP, echocardiography, anterior mitral leaflet area, left ventricular end-diastolic internal diameter, vertebral left atrial size, veterinary regenerative medicine, SPRING study, allogeneic stem cell therapy, pilot clinical study, dog heart disease, biomarker changes
News Source: Drew Townsend. (November 16, 2026). Stem Cell Therapy Linked to Cardiac Biomarker Changes in Canine Pilot Study. Scienmag.



